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Abstract 
Multiple DNA methylation changes in the cancer methylome are associated with the acquisition of 
drug resistance; however it remains uncertain how many represent critical DNA methylation drivers 
of chemoresistance. Using isogenic, cisplatin sensitive/resistant ovarian cancer cell lines and 
inducing re-sensitisaton with demethylating agents, we aimed to identify consistent methylation and 
expression changes associated with chemoresistance. Using genome-wide DNA methylation profiling 
across 27 578 CpG sites, we identified loci at 4092 genes becoming hypermethylated in 
chemoresistant A2780/cp70 compared to the parental sensitive A2780 cell line. Hypermethylation at 
gene promoter regions is often associated with transcriptional silencing, however expression of only 
245 of these hypermethylated genes becomes down-regulated in A2780/cp70 as measured by 
microarray expression profiling. Treatment of A2780/cp70 with the demethylating agent 2-deoxy-5’-
azacytidine induces re-sensitisation to cisplatin and re-expression of 41 of the down-regulated 
genes.  13/41 genes were consistently hypermethylated in further independent cisplatin-resistant 
A2780 cell derivatives. CpG sites at 9 of the 13 genes (ARHGDIB, ARMCX2, COL1A, FLNA, FLNC, MEST, 
MLH1, NTS, PSMB9) acquired methylation in ovarian tumours at relapse following chemotherapy or 
chemoresistant cell lines derived at the time of patient relapse. Furthermore, 5/13 genes (ARMCX2, 
COL1A1, MDK, MEST, MLH1) acquired methylation in drug-resistant ovarian cancer sustaining (side 
population) cells. MLH1 has a direct role in conferring cisplatin sensitivity when reintroduced into 
cells in vitro. This combined genomics approach has identified further potential key drivers of 
chemoresistance whose expression is silenced by DNA methylation that should be further evaluated 
as clinical biomarkers of drug resistance.  
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Introduction 
Ovarian cancer often presents at an advanced stage with limited chances for curative treatment 
(Ozols 2004). Common treatment strategies include debulking surgery in combination with 
chemotherapy, which usually consists of a platinum-based compound such as cisplatin/carboplatin 
and a taxane, e.g. paclitaxel. Despite responses to first-line chemotherapy in a high proportion of 
patients, many will relapse and eventually develop resistance to currently available treatment 
options, making the acquisition of clinical drug resistance one of the major challenges in ovarian 
cancer therapy and a limiting factor in patient survival (Cannistra 2004).  
Platinum drugs are DNA cross-linking agents exerting their effect mainly via the formation of intra-
strand adducts between adjacent guanosines which interfere with transcription and replication 
eventually leading to cell death (Kartalou and Essigmann 2001, Wang and Lippard 2005). Several 
mechanisms have been suggested to participate in conferring platinum-resistant properties to a 
tumour cell such as genetic alterations in genes involved in DNA repair, drug uptake, apoptosis, cell 
cycle control and IGF signalling pathways (Broxterman et al 2009, Eckstein et al 2009, Edwards et al 
2008, Johnstone et al 2002, Luqmani 2005). More recently, it has been proposed that, in addition to 
genetic changes, aberrant epigenetic marks can critically contribute to the acquisition of drug 
resistance (Sharma et al 2010). In cisplatin-resistant cancer cells, in particular, multiple DNA 
methylation changes at promoter CpG islands and associated transcriptional gene silencing have 
been reported (Chang et al 2010, Dai et al 2008, Teodoridis et al 2005). For instance, methylation at 
MLH1, a mismatch repair gene, is acquired in about 25%-35% of ovarian cancer patients following 
platinum-based chemotherapy and has been shown to be associated with poor patient survival 
(Gifford et al 2004, Strathdee et al 1999). Importantly, reversal of MLH1 epigenetic silencing by 
demethylation or re-expression of the gene was demonstrated to re-sensitise tumour cells to 
subsequent chemotherapeutic treatment in vitro and in vivo (Papouli et al 2004, Plumb et al 2000, 
Steele et al 2009). MLH1 might, therefore, represent one of the key genes driving chemoresistance 
in ovarian cancer cell lines. However, while the role of methylation changes at MLH1 has been well 
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characterized, for the majority of aberrant DNA methylation events it is not particularly clear 
whether they are associated with response to chemotherapy or are just occurring by chance due to 
a methylator phenotype or simply as random methylation events (Issa 2004) during platinum 
selection or DNA damage induction. In analogy to the concept of ‘driver and passenger’ mutations 
emerging during carcinogenesis, methylation changes could either represent ‘drivers’ of 
chemoresistance based on their potential to provide the cell with a selective advantage or 
‘passenger’ events with no substantial impact on chemosensitivity (Greenman et al 2007). 
We hypothesized that, in analogy to driver mutations, there might be a subset of epigenetic changes 
which are causally associated with the acquisition of chemoresistance. In order to identify the 
proportion of epigenetically altered genes driving platinum resistance in ovarian cancer we have 
analysed acquired DNA methylation changes in a human ovarian cancer cell line model of cisplatin 
resistance and expression changes associated with acquired resistance or following re-sensitisation 
with demethylating agents. We then examined the generality of the changes observed to ovarian 
tumours at relapse following chemotherapy.  
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Results 
Cisplatin selects preferentially for DNA hypermethylation in A2780 chemoresistant cell lines 
To identify DNA methylation changes associating with changes in gene expression and differential 
cisplatin chemosensitivity we used the human A2780 ovarian cell line model which consists of 
sensitive and matched isogenic platinum-resistant lines derived from A2780 cells by repeated 
exposures to increasing levels of cisplatin (Anthoney et al 1996). We performed genome-wide DNA 
methylation profiling of resistant A2780/cp70, A2780/MCP1 and A2780/MCP6 compared to non-
selected A2780p5 and A2780p6 clones employing Infinium HumanMethylation27 BeadArrays which 
comprise 27 578 CpG sites across more than 14 000 genes. In a first step, differentially methylated 
genes were extracted as showing a significantly increased or decreased difference of beta (|Δβ|) 
corresponding to a false discovery rate (FDR) < 0.05 estimated from biological replicates within the 
study (|Δβ|~0.1) between A2780/cp70 versus A2780 at ≥ 1 associated CpG site (see Material and 
Methods). Using these criteria, we identified multiple methylation changes between A2780/cp70 
versus A2780 (Figure 1): ≥ 1 CpG site at 4092 genes were hypermethylated, while only 1289 genes 
became hypomethylated following exposure to cisplatin, suggesting that hypermethylation occurs 
more frequently than hypomethylation during the process of selection for acquired cisplatin 
chemoresistance.  
 
Methylation changes in cisplatin resistant lines associate with gene expression changes in only a 
subset of genes 
In a second step, we examined the expression profiles of sensitive A2780 and resistant A2780/cp70 
cell clones using Affymetrix HG-U133 Plus 2.0 Arrays and identified differentially expressed genes by 
applying rank products analysis (Breitling et al 2004). Aberrant DNA methylation at CGI has been 
shown to critically affect gene expression and is strongly associated with transcriptional repression 
(Esteller 2008, Jones and Baylin 2002). We assumed that expression changes associating with 
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hypermethylation in chemoresistant A2780/cp70 as compared to A2780 would likely represent 
silencing events associated with the drug-resistant phenotype. We identified a total of 1370 genes 
showing significant gene expression changes with 687 genes going up and 683 genes going down in 
resistant versus sensitive cell lines. We further filtered for those genes where hypermethylation 
associated with reduced expression in chemoresistant A2780/cp70 cells. Of the 4092 genes 
hypermethylated in A2780/cp70, 3823 (93%) genes are present on the HG-U133 Plus 2.0 Array. 
Combined analysis revealed that only a small proportion of changes in methylation correlated with 
expression changes, with 245 genes becoming hypermethylated and down-regulated following 
selection for cisplatin resistance in A2780/cp70.  
 
Only a small proportion of hypermethylated genes that are down-regulated become re-expressed 
following treatment with Decitabine  
In order to identify DNA methylation changes associating with changes in gene expression and 
differential cisplatin chemosensitivity in this cell line model, we combined our data with expression 
profiles of A2780/cp70 cells treated with either the DNA methyltransferase inhibitor (DNMTi) 2-
deoxy-5’-azacytidine (Decitabine, DAC), the histone deacetylase inhibitor (HDACi) Belinostat or a 
combination of both at conditions and time point known to induce chemosensitisation in this cell 
line (Steele et al 2009). We reasoned that genes effecting drug sensitivity via hypermethylation-
associated silencing in chemoresistant cells would become switched backed on following 
pharmacological intervention of methylation and/or deacetylation. DNMTi treatment can act 
synergistically with an HDACi in restoring gene expression (Cameron et al 1999) and sequential 
exposure of cells to DNMTi and HDACi might, therefore, lead to re-expression of additional genes.  
Treatment with DAC resulted in re-expression of 41 out of the 245 genes which were 
hypermethylated in addition to being down-regulated in A2780/cp70 cells (Figure 2A, Table S1). 45 
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genes became switched back on following combined treatment with DAC and the HDACi Belinostat.  
Exposure to Belinostat alone re-induced the expression of only 10 genes which were down-regulated 
in addition to being hypermethylated in untreated A2780/cp70 cells. Comparison of the gene lists 
showed a big overlap between the 41 (DAC) and 45 (DAC+Belinostat) re-expressed genes with 40/41 
genes being contained within the list of 45 genes suggesting that addition of the HDACi does not add 
substantially to the number of genes re-activated by DAC alone. We further compared DNA 
methylation profiles of A2780/cp70 cells following drug treatment with untreated A2780/cp70. 
Using a differential methylation cut-off of |Δβ|≥0.1 we validated that all of the 41 DAC-responsive 
genes became demethylated at ≥ 1 associated CpG site following treatment with DAC. This 
substantiates that re-expression of the 41 DAC-induced genes was truly mediated by DNA 
demethylation (Figure S2).  
 
A small set of 13 genes are strong candidates as epigenetically silenced cisplatin resistance drivers  
In order to identify drug resistance-associated methylation changes which were independent of 
clonal effects we further filtered for genes showing consistent hypermethylation of re-induced genes 
in independently selected cisplatin-resistant A2780 derivatives. Out of the 4092 hypermethylated 
genes initially identified in A2780/cp70, 1824 genes were also hypermethylated in the two 
independent cisplatin-resistant derivatives A2780/MCP1 and A2780/MCP6 (Figure 3). 
Among those 1824 hypermethylated genes a small proportion of only 13 genes (ARHGDIB, PSMB9, 
HSPA1A, ARMCX2, MEST, FLNC, MLH1, MDK, GLUL, FLNA, NTS, COL1A1 and NEFL) became re-
expressed in A2780/cp70 following treatment with DAC (Table 1, Figure 3A, Figure 4A). Epigenetic 
silencing of MLH1 has previously been shown to be a clinically relevant mechanism of acquired 
cisplatin resistance in ovarian cancer (Gifford et al 2004) and re-expression of MLH1 confers 
increased cisplatin chemosensitivity in xenograft models (Plumb et al 2000). MLH1 was identified 
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amongst the list of 13 genes supporting our approach and substantiating the notion that aberrant 
methylation of a small set of genes can putatively drive the acquisition of cisplatin resistance.  
Combined DAC and Belinostat treatment did not markedly increase the number of re-expressed 
genes with 14 commonly hypermethylated genes becoming switched back on in the resistant cell 
line (ARHGDIB, PSMB9, HSPA1A, ARMCX2, MEST, FLNC, MLH1, MDK, GLUL, NTS, COL1A1, NEFL, 
SERPINB2 and HIST1H2BF). Again, we observed a strong overlap between genes being re-induced 
following DAC and combined DAC/Belinostat treatment. Only SERPINB2 and HIST1H2BF were 
exclusively DAC/Belinostat-responsive suggesting that synergistic demethylation and acetylation is 
necessary for their re-activation. In contrast, only one gene (GLUL) was being re-induced following 
Belinostat treatment alone in addition to being consistently hypermethylated across resistant A2780 
cell lines. Interestingly, GLUL was also re-activated following DAC and combined DAC/Belinostat 
treatment. However, the effect of Belinostat alone on GLUL expression was very subtle with a low 
fold change suggesting that DAC-induced demethylation is still required for full restoration of gene 
activity. 
We further validated our array-based findings in the A2780 cell line model by using bisulphite 
pyrosequencing and qRT-PCR. We arbitrarily chose the three genes MEST, FLNC and ARHGDIB which 
were commonly hypermethylated in independent cisplatin-resistant cell lines (Figure 4) and became 
re-expressed following DAC as well as combined DAC/Belinostat treatment. FLNC and MEST are both 
associated with CGIs whereas ARHGDIB does not contain a CGI. Acquired hypermethylation was 
confirmed for MEST, FLNC and ARHGDIB in resistant versus sensitive A2780 cell lines (Figure 4B). The 
observed differences in CpG methylation between sensitive and resistant lines at 39%, 42% and 27% 
corresponded to a Δβ of 0.38, 0.43 and 0.23 for MEST, FLNC and ARHGDIB, respectively (Figure 4). 
Hypermethylation of the three genes was associated with down-regulation in A2780/cp70 resistant 
cells as compared to A2780 (Figure 4B and 4C). We also tested mRNA expression of the three genes 
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in independent cisplatin-resistant A2780/MCP1 and A2780/MCP6 and found down-regulation to be 
associated with hypermethylation in these cell lines (data not shown). 
 
Candidate drug resistance genes commonly acquire methylation in independent in vivo-derived 
ovarian chemoresistant cells and in tumours at relapse 
In order to address how the small set of epigenetically inactivated candidate resistance drivers 
impacts on clinical drug resistance we evaluated their methylation status in three independent pairs 
of in vivo-derived chemonaive and chemoresistant ovarian tumour cell lines derived from patients 
prior to chemotherapy and at the time of developing clinical resistance (Langdon et al 1988). Using a 
difference of |Δβ|≥0.1 we observed acquired methylation in 6 out of the 13 genes (ARHGDIB, 
ARMCX2, COL1A1, FLNA, MEST, MLH1) in chemoresistant, post-chemotherapy cell lines (Table 2).  
One hypothesis of how drug resistance evolves implies the expansion of so-called tumour-initiating 
or cancer sustaining cells (CSC) (Rajasekhar et al 2008). This population of cells is thought to share 
many characteristics with normal stem cells including the capacity to self-renew and to survive drug 
treatment (Dean et al 2005). According to this paradigm, the acquisition of drug-resistance results 
from repopulation of the tumour with inherently drug-resistant CSC following chemotherapeutic 
treatment. We examined if candidate drug resistance drivers showed altered methylation in CSC 
obtained from an ovarian cancer cell line by comparing the β values of the set of 13 genes in 
independently sorted side populations (SP) of IGROV1 cells (n=2) versus non-SP. We have previously 
shown that IGROV1 SP have tumour stem cell like properties; including ability to form tumours in 
NOD/SCID mice at low cell number, enhanced ability to grow as spheroids, ability to repopulate SP 
and non-SP cells and expression patterns with significant enrichment for known stem cell markers 
(Rizzo et al 2011). Applying a |Δβ|≥0.1 we observed 5 genes as having higher methylation in IGROV1 
CSC populations (ARMCX2, COL1A1, MEST, MDK and MLH1) (Table 2). Notably, 4 of these genes had 
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acquired methylation in in vivo-derived cisplatin resistant cell lines (ARMCX2, COL1A1, MEST and 
MLH1) supporting enrichment of methylation at these loci in chemoresistant cell populations.  
We further evaluated the methylation status of the 13 candidate genes in clinical specimens using 7 
pairs of matched primary ovarian tumours and tumours at time of relapse. Methylation of 8/13 
genes was acquired in tumours following platinum-based chemotherapy (Table 2). Three of these 
genes (ARMCX2, MEST and MLH1) were found to have higher methylation in chemoresistant in vivo-
derived cell lines, CSC populations and tumours at relapse supporting the clinical relevance of 
changes at these loci.  
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Discussion 
Substantial DNA methylation changes have previously been reported to occur during the acquisition 
of platinum resistance. Among those changes hypermethylation at CGI promoters and associated 
epigenetic silencing are prevalent in various cell line models (Chang et al 2010, Dai et al 2008, Li et al 
2009) and are thought to, either alone or in combination with genetic changes, account for the loss 
of expression of key genes in the platinum-responsive phenotype. However, our knowledge of 
whether these DNA methylation changes and aberrantly inactivated genes are actually driving 
chemoresistance is limited. By integrating drug induced re-sensitisation, methylation and expression 
profiling in an isogenic, cisplatin-resistant ovarian cancer cell line model, we present evidence that 
the proportion of key DNA methylation and linked expression changes associating with response to 
chemotherapy is surprisingly small. Our results indicate that less than 1% of hypermethylated genes 
in independent platinum-resistant ovarian cancer cell lines account for the acquisition of platinum 
resistance. Indeed, by comparing methylation changes in multiple independent cisplatin resistant 
derivatives of A2780 we identify as few as 13 key genes that acquire methylation at associated CpG 
sites. However, we show that a high proportion of the loci identified acquire methylation in ovarian 
tumours at relapse (8/13) and are differentially methylated in drug resistant ovarian tumour 
sustaining (stem) cells (5/13). Therefore, methylation at CpG sites at these genes are key candidate 
epigenetic drivers of acquired drug resistance.  
Few previous studies established hypermethylation as a marker of platinum-resistant ovarian cancer 
cell lines on an epigenome-wide basis (Dai et al 2008, Li et al 2009). While the mechanism of how 
drug-resistant cells accumulate methylation is unresolved there are clear examples showing an 
association between epigenetic silencing of specific genes and drug response. For example, acquired 
MLH1 CGI hypermethylation and associated gene inactivation is observed following platinum-based 
chemotherapy in ovarian cancer and has been associated with poor clinical outcome (Gifford et al 
2004). Consequently, re-expression of MLH1 in chemoresistant cell lines has been shown to partially 
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restore their sensitivity to subsequent cisplatin therapy (Papouli et al 2004, Plumb et al 2000). 
Notably, our list of methylation-dependent genes included MLH1, substantiating the hypothesis that 
we have identified a specific subset of genes that drive the acquisition of drug resistance. It has to be 
noted however, that full re-sensitisation of cells to platinum-based drugs could not be achieved via 
MLH1 re-expression alone in cell line models, in contrast to reversal of methylation using 
demethylating agents which fully restores chemosensitivity and induces re-expression of multiple 
genes  (Papouli et al 2004, Plumb et al 2000). These observations support the idea that the induction 
of additional repressed genes to MLH1 is vital for full restoration of drug sensitivity in these models. 
However, this also illustrates the challenges in demonstrating direct effects of a gene on 
chemosensitivity in vitro based on gene reintroduction, where the effects may be small or require 
inactivation of multiple genes. Our results indicate that several methylation changes are directly 
associated with chemosensitisation induced by demethylating agents combined with HDAC 
inhibitors. Similar observations have been reported in other tumour types (Chang et al 2010), 
however, our data also reveal that epigenetic alterations associated with sensitivity to cisplatin occur 
at a few selected genes rather than large numbers of loci in this cell line model (Glasspool et al 
2006).  
The group of epigenetically inactivated genes was up-regulated by DAC and also the combined DAC 
and Belinostat treatment, but remained unaffected by Belinostat alone with the exception of GLUL. 
Consistent with previous reports the inhibition of HDAC did not add extensively to the number of re-
expressed genes, with only 2 additional genes (SERPINB2 and HIST1H2BF) being re-induced 
(Cameron et al 1999, Suzuki et al 2002). Addition of an HDACi can markedly increase the level of 
gene re-expression such as MLH1 in vitro and in vivo (Steele et al 2009), but may not convert further 
genes to re-express. While other studies reported lack of methylation of genes responsive to HDACi 
and, partially, to DNMTi (Suzuki et al 2002) our analysis specifically extracted genes which were 
hypermethylated in chemoresistant cell lines. One explanation for this discrepancy could be the 
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method we used for identification of differentially expressed genes. We applied the rank products 
method based on our aim to detect differences that consistently rank highly across any number of 
replicate experiments and which are most likely to have biological significance. This form of analysis 
avoids identifying a fold change which exceeds an arbitrary threshold. Conversely, this method can 
identify subtle changes and these subtle changes may be missed by other methods.  
Our subset of candidate drug resistance drivers was identified by using an isogenic cell line model. 
While this model allows identifying changes ultimately linked to cisplatin exposure, detection of 
genes in identical rather than in diverse genetic settings, as well as issues surrounding in vitro 
selection, may be a limitation to the value of this gene set. However, we observed increased 
methylation of six out of the 13 candidate genes in at least one of three cisplatin-resistant in vivo-
derived cell lines. We further observed acquired methylation of five out of these six genes in 
tumours at relapse. Although our set of matched tumour pairs pre and post chemotherapy was small 
due to the clinical challenges in obtaining such matched samples, this nevertheless suggests that the 
acquisition of methylation at these genes may be a common event occurring during acquired 
cisplatin resistance and may be clinically relevant. Notably, the low frequency at which epigenetic 
changes are acquired at candidate drug resistance drivers shows analogies to driver mutations which 
often present at a low frequency (Wood et al 2007) and might, therefore, be missed within a small 
set of tumours. Interestingly, we also observed increased methylation at three (ARMCX2, MEST, 
MLH1) out of these five commonly hypermethylated candidate genes in drug-resistant sustaining 
(SP) cells isolated from the human ovarian tumour cell line IGROV1 as compared to the bulk of the 
tumour cells. Our observation could indicate that hypermethylation and epigenetic silencing of this 
subset of three genes is already present in stem cells.  Since SPs are believed to contain the cells 
responsible for maintenance of long-term growth of ovarian cancer (Bapat et al 2005, Szotek et al 
2006) re-growth of these cells could be contributing to manifesting a drug-resistant phenotype 
(Agarwal and Kaye 2003).   
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Silencing of MLH1 leads to loss of DNA mismatch repair, which in turn has been suggested to lead to 
platinum DNA damage tolerance due to translesion synthesis, reduced replication stalling or reduced 
signalling of cell death pathways (O'Brien and Brown 2006, Stojic et al 2004, Yoshioka et al 2006). 
However, little is known about the function in drug resistance of the other genes found to commonly 
acquire methylation in tumours and cell lines at relapse and in drug-resistant SP populations. 
ARMCX2 might have a role in tumour suppression based on the presence of an armadillo repeat 
motif which is found in other proteins fulfilling functions in cell proliferation, migration, maintenance 
of tissue integrity, and tumourigenesis and has been involved in development (Smith et al 2005). 
MEST, a maternally imprinted gene, has been implicated in embryonic growth and maternal 
behaviour (Lefebvre et al 1998) and loss of MEST imprinting has been reported in breast and lung 
cancers (Nakanishi et al 2004, Pedersen et al 2002). Interestingly, it has recently been shown that 
MEST is a negative regulator of the Wnt pathway and that MEST knockdown might activate Wnt 
signalling (Jung et al 2011). Epigenetic regulation of Wnt pathway genes has previously been shown 
to be associated with patient survival following platinum-based chemotherapy and chemoresistance 
in ovarian cancer (Dai et al 2011, Peng et al 2011).  
Taken together, we have identified a key subset of genes potentially driving acquired drug resistance 
in ovarian cancer from the large number of epigenetic changes occurring following chemotherapy. 
As well as providing novel insight into mechanisms of drug resistance, this has identified candidate 
biomarkers for further evaluation in future clinical studies, including potential stratification 
biomarkers in clinical trials of epigenetic therapies which reverse the acquired resistance phenotype. 
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Materials and Methods 
Cell lines: In vitro-derived A2780p5, A2780p6, A2780/cp70, A2780/MCP1 and A2780/MCP6 cell lines 
(Anthoney et al 1996) were obtained from Dr. Robert F. Ozols (Fox Chase Cancer Centre, 
Philadelphia, PA, USA). PEO1, PEO4, PEO14, PEO23, PEA1 and PEA2 in vivo-derived cell lines 
(Langdon et al 1988) were obtained from Professor Hani Gabra (Imperial College, London, UK). 
Isolation of side and non-side populations of IGROV1 cells was performed as described previously 
(Rizzo et al 2011). The identity of the cell lines was verified by DNA genotyping. All cell lines were 
grown in RPMI-1640 supplemented with glutamine (2mM) and 10% fetal bovine serum.  
 
Tumour Samples: Seven pairs of matched serous epithelial ovarian tumours pre chemotherapy and 
at relapse were obtained from the University Medical Center Groningen, The Netherlands. 
Appropriate ethical approval for all samples collected was obtained.  
Methylation profiling: All array-based methylation profiling was performed using the Infinium 
HumanMethylation27 BeadChip (Illumina, San Diego, CA, USA) except for DNA methylation profiling 
following treatment with epigenetic remodelling agents which was performed using Infinium 
HumanMethylation450 BeadChips (Illumina, San Diego, CA, USA).  1 µg genomic DNA was bisulphite 
modified using the EZ DNA Methylation Kit (Zymo Research, Irvine, CA, USA). 200 ng of converted 
DNA was further processed to run BeadArrays according to the manufacturer’s instructions. Each 
locus is represented by fluorescent signals from two bead types corresponding to the methylated 
(M) and unmethylated (U) alleles, respectively. The raw signals of unmethylated and methylated 
bead types were background corrected and computed into a beta value using the BeadStudio 
software Methylation Module (version 1.0.5) (Illumina). The beta value represents the ratio of the 
intensity of the methylated bead type to the combined locus intensity: β= Max(M, 
0)/[Max(M,0)+Max(U,0)+100] and reflects the methylation status of a specific CpG site. Subsequent 
analysis was carried out in R (version 2.10.1).  
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The reproducibility of the BeadChips was evaluated using biological (independent bisulphite 
modifications of two independently prepared DNAs) and technical replicates (bisulphite conversion 
of identical DNA) of matched chemosensitive/chemoresistant ovarian cancer cell lines PEO1/PEO4. 
Beta values of biological and technical replicates of PEO1 and PEO4 were highly correlated with r2 
values > 0.99 (supplementary Figure S1).  
Gene annotation was carried out using the Mar. 2006 (NCBI/36/hg18) assembly at the UCSC 
database (genome.ucsc.edu/). Individual CpG sites located within a CGI as defined by Gardiner-
Garden (1987) were linked to an associated gene if the CGI was within 2 kb distance from the 
respective transcription start site (Saxonov et al 2006). Non-CGI-related CpG sites were linked to a 
gene if they were located within 2 kb from the transcription start site.  
For pairwise differential methylation analysis, the difference of two biological replicates of the 
ovarian cancer cell lines PEO1 and PEO4 was calculated as the expected difference (null distribution). 
The observed difference was calculated from the paired samples. Using bootstrap resampling 
method, we extracted the same number of CpG sites (n=27 578) from the null distribution 200 
times. Each time, a FDR was calculated using the formula below. The median of FDRs was used as an 
estimation of the probability that CpG sites with differential methylation above the selected cut-off 
were identified by chance. This median FDR was set at 0.05 corresponding to |Δβ|≥0.1.  
 
 
In order to filter for differentially methylated CpG sites in the A2780 cell line model mean beta 
values across sensitive cell clones were used.  
Bisulphite Modification and Pyrosequencing: 1 μg of genomic DNA was bisulphite modified using 
the EpiTect Bisulphite Kit (Qiagen, West Sussex, UK) according to the manufacturer's instructions. 
datarealincutoffoversitesCpG
datanullincutoffoversitesCpGFDR
______#
______#
=
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Pyrosequencing primer sets covering differentially methylated CpG sites in the ARHGDIB, FLNC and 
MEST gene promoters were ARHGDIB_PYRO_F: 5’-Biotin-TGGGAATAGAAGTGAGTGGTATAA-3’, 
ARHGDIB_PYRO_R: 5’-CCTATTCCTTTACACTACCTATCT-3’, ARHGDIB_PYRO_S: 5’-
CAACATTCTTATCAATTAATAACAC-3’, FLNC_PYRO_F: 5’-TGGAGGGAGAGAGAGTTAG-3’, 
FLNC_PYRO_R: 5’-Biotin-CTTACCCACCCACTTAAAATACTCATTAC-3’, FLNC_PYRO_S: 5’- 
AGAAGTTGGAGAGGA-3’, MEST_PYRO_F: 5’-Biotin-GTGGGTTATATTAGTTTTAGGGGTAG-3’, 
MEST_PYRO_R: 5’-CCTTTCCAACCTCCAAAACTAACTAT-3’, MEST_PYRO_S: 5’-
AAATTATATAACTTTTATATTCTC-3’. Pyrosequencing-PCR was performed in duplicate for each sample 
in a 25 μl volume containing 0.2 μl Faststart Taq polymerase (Roche, Welwyn Garden City, UK), 2.5 μl 
Faststart Buffer (Roche), 0.2 mM dNTPs (Applied Biosystems, Warrington, UK), 75 ng primers (each) 
and 1 μl of modified DNA template using the following conditions: 95°C for 6 min, 35 cycles of 95°C 
for 30 sec, 60°C for 30 sec, 72°C for 30 sec followed by 72°C for 5 min. Pyrosequencing of PCR-
products was performed using the PyroGold Reagent Kit (Qiagen) according to the manufacturer’s 
instructions. The methylation percentage of CpG sites for individual genes was calculated by using 
the Pyro Q-CpG software (version 1.0.9) and then averaged across sensitive and resistant A2780 
derivatives, respectively. 
 
Treatment of cells with DNMT inhibitor and/or HDAC inhibitor: Cells were treated at 50% 
confluence with 0.1 µM 5-aza-2'-deoxycytidine (Decitabine, DAC) (Sigma-Aldrich, St. Louis, MO, USA) 
or 0.1 µM Belinostat or mock-treated for 48 hours. DAC was replaced after 24 hours. For combined 
DAC/Belinostat treatment DAC (0.1 µM) was added for 48 hours with Belinostat (0.1 µM) being 
added for an additional 24 hours following the initial 24 hour DAC treatment. Cells were harvested 
96 hours following drug removal.  
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RNA extraction and microarray analysis. Total cellular RNA was isolated using the RNAeasy kit 
(Qiagen) according to the manufacturer's instructions. RNA quality was verified using the Agilent 
2100 Bioanalyser (Agilent, Wokingham, UK). Expression profiling was carried out using the Human 
Genome U133 Plus 2.0 Array (Affymetrix, High Wycombe, UK) following the manufacturer's 
recommendations. Three biological replicates were used for each sample. The raw expression data 
were normalised as previously described (Irizarry et al 2003). Subsequent analysis was performed in 
R (version 2.10.1). Data were log2 transformed and signal intensity and statistical significance were 
established for each transcript. Rank products (Breitling et al 2004) was applied to identify 
differentially expressed genes using individual probes and significance was set at a FDR < 0.05.  
Data deposition. Methylation and expression profiling data are available in NCBI’s Gene Expression 
Omnibus (GEO accession number: GSE28648) and can be accessed under: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=dvmfbkgeuuuqija&acc=GSE28648. 
 
Reverse transcription and Real-time-PCR. 2 μg RNA were reverse transcribed into cDNA using 
SuperScript II (Invitrogen) and subsequently used as a template in quantitative real time (qRT-PCR) 
experiments to amplify products for MEST, FLNC, ARHGDIB and GAPDH. Primer sequences were 
MEST_qRT_2F: 5’-CGGCCATGGTGCGCCGAGAT-3’, MEST_qRT_2R: 5’-ACGCAGCAAGCAGGGGCACG-3’, 
FLNC_qRT_1F: 5’-GTGCCCAAGGTCGCTGGGTTACA-3’, FLNC_qRT_1R: 5’-TCCCAGGGCCATGCCCACGTT-
3’, ARHGDIB_qRT_1F: 5’-AACGCTGCTGGGAGATGGTCCTGT-3’, ARHGDIB_qRT_1R: 5’-
ACCAGGGTGAGCCGGGTGACAA-3’, GAPDH_qRT_F: 5’-CCTGTTCGACAGTCAGCCG-3’ and 
GAPDH_qRT_R: 5’-CGACCAAATCCGTTGACTCC-3’. qRT-PCR was carried out in triplicate with the 
Biorad CFX96 Real-Time system using SYBR Green JumpStart Taq ReadyMix (Sigma-Aldrich) and 
amplification parameters: 95°C for 3 min, 42 cycles of 95°C for 10 sec, 60°C for 10 sec and 72°C for 
30 sec, followed by 95°C for 10 sec and temperature increments from 72 °C - 95 °C for 5 sec. Relative 
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expression was determined by applying the comparative Ct method (Schmittgen and Livak 2008) 
using GAPDH as the internal control gene.  
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Figure legends 
Figure 1. Hypermethylation is prevalent in cisplatin-resistant A2780 cell clones. Scatter plots of β 
values show differentially methylated loci between A2780 sensitive (average of A2780p5/A2780p6) 
versus resistant derivatives A2780/cp70, A2780/MCP1 and A2780/MCP6 (yellow) as measured by 
Infinium HumanMethylation27 BeadArrays. The differential methylation cut-off (red and green solid 
line) was estimated from the difference between biological replicates of cell lines PEO1 and PEO4 
(blue) by controlling FDR<0.05. 
Figure 2. Re-expression of genes in chemoresistant A2780/cp70 cells following treatment with 
epigenetic remodelling agents. 41 genes (DAC), 45 genes (DAC+Belinostat) or 10 genes (Belinostat) 
become re-activated following treatment, respectively. Venn diagrams show the overlap between 
number of genes being hypermethylated in untreated A2780/cp70 (green circle), being down-
regulated in untreated A2780/cp70 (pink circle) and genes with increased expression following drug 
exposure in A2780/cp70 as compared to A2780 cells (blue circle). 
Figure 3. A small percentage of consistently hypermethylated genes is affected following re-
sensitisation with epigenetic remodelling agents. Out of 1824 genes hypermethylated in 
independent cisplatin-resistant A2780 derivatives only 13 genes become re-expressed following DAC 
treatment, 14 genes become re-activated following combined DAC and Belinostat treatment and 
only 1 gene becomes re-expressed following Belinostat treatment. Venn diagrams show the overlap 
between genes being hypermethylated in chemoresistant A2780/cp70, A2780/MCP1 and 
A2780/MCP6 (green circle), being down-regulated in untreated A2780/cp70 (pink circle) and genes 
with increased expression following drug exposure in A2780/cp70 as compared to A2780 cells (blue 
circle). 
Figure 4. Methylation and expression analysis of genes getting re-expressed following DAC 
treatment in A2780 resistant cell lines. A) Heatmap of the 13 DAC-regulated genes showing 
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increased methylation in resistant A2780/cp70, A2780/MCP1 and A2780/MCP6 cell clones as 
compared to A2780 sensitive lines (|Δβ|≥0.1). B) Validation of hypermethylation of DAC-regulated 
candidate genes in A2780 resistant cell lines by bisulphite pyrosequencing. Average methylation 
values across A2780 sensitive and resistant cell lines are shown for three genes. Pyrosequencing 
assays show average methylation values across 2 CpG sites for MEST (CpG site No. 1 relates to 
Illumina ID cg08077673), 7 CpG sites for FLNC (CpG site No. 6 relates to Illumina ID cg02661879) and 
3 CpG sites for ARHGDIB (CpG site No. 2 relates to Illumina ID cg10925082) covering the 
differentially methylated CpG site shown in methylation profile A). C) Validation of down-regulation 
of DAC-regulated candidate genes in A2780 resistant cell lines by qRT-PCR. The fold reduction in 
A2780/cp70 cells versus A2780 sensitive cells is shown for three genes.  
 
Figure S1. Comparison of the methylation profiles of technical and biological replicates of the two 
cell lines PEO1 and PEO4 shows a high level of agreement between all replicates with correlation 
coefficients r2> 0.99. Scatter Plots depict the beta values across > 27,000 CpG sites of independent 
hybridisation experiments or independent DNA preparations of PEO1 and PEO4, respectively. TR, 
technical replicate; BR, biological replicate 
 
Figure S2. Re-expression of the 41 hypermethylated and down-regulated genes is mediated by DNA 
demethylation following treatment with DNMTi. Scatter plots show β values of associated CpG sites 
of the 41 genes between A2780/cp70 untreated versus A2780/cp70 treated with DAC, A2780/cp70 
treated with combined DAC and Belinostat or A2780/cp70 treated with Belinostat alone as 
measured by Infinium HumanMethylation450 BeadChips. A minimum of 1 associated CpG site 
becomes demethylated following DAC treatment in the 41 genes. Combined DAC and Belinostat 
treatment also results in demethylation whereas no demethylation occurs following treatment with 
the HDACi (Belinostat) alone. The differential methylation cut-off (blue dotted line) in untreated 
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versus treated A2780/cp70 was set at |Δβ|≥0.1 with red dots indicating associated CpG sites with 
|Δβ|≥0.1 and black dots representing CpG sites with 0<|Δβ|<0.1. 
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Tables  
Table 1. DAC-induced genes being hypermethylated and down-regulated in A2780/cp70 
Gene 
symbol 
Gene name Location  Biological Role DM 
CGI 
DM non- 
CGI 
ARHGDIB Rho GDP dissociation inhibitor β 12p12.3 GDP/GTP exchange N1 Y 
ARMCX2 armadillo repeat containing, X-
linked 2 
Xq21.3-
q22.2 
development, tissue integrity N1 Y 
COL1A1 collagen, type I, alpha 1 17q21.3 extracellular matrix component Y N 
FLNA filamin A, alpha Xq28 cytoskeleton reorganisation, motility 
and migration, signal transduction 
Y N 
FLNC filamin C, gamma 7q32-q35 actin cytoskeleton reorganisation Y Y 
GLUL glutamate-ammonia ligase 1q31 glutamine synthesis Y N3 
HSPA1A heat shock 70kDa protein 1A 6p21.3 protein binding, stress response Y N 
MDK midkine 11p11.2 growth Y Y 
MEST mesoderm specific transcript 
homolog (mouse) 
7q32 development Y Y 
MLH1 mutL homolog 1, colon cancer, 
nonpolyposis type 2 (E.coli) 
3p22.3 DNA mismatch repair Y Y 
NEFL neurofilament, light polypeptide 8p21.2 axoskeleton N2 Y 
NTS neurotensin 12q21 neuromodulator, growth N1 Y 
PSMB9 proteasome subunit (prosome, 
macropain), beta type, 9 
6p21.3 antigen processing  N Y 
Abbreviations: DM= differentially methylated, CGI= CpG island, N=No, orf=open reading frame, Y=Yes, 1 no CGI present, 2 no probe in CGI 
present, 3 no probe outside of CGI present 
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Table 2. Acquired methylation (|Δβ|≥0.1) of candidate drug resistance drivers in drug-resistant in 
vivo-derived ovarian cancer cell lines, side populations and tumours at relapse  
                            Tissue                
Genes (Probe ID) PEO1/4 PEO14/23 PEA1/2 NSP1/SP1 NSP2/SP2 Pair 1 Pair 2 Pair 3 Pair 4 Pair 5 Pair 6 Pair 7
ARMCX2     (cg22343001) 0.460 0.191 0.168 0.204 0.112
ARMCX2     (cg19055639) 0.104
MEST            (cg09059945) 0.646 0.134 0.151 0.193
MEST            (cg08077673) 0.851 0.108 0.123 0.109 0.400
MEST            (cg01888566) 0.682 0.157 0.407
MEST            (cg02490034) 0.548 0.290 0.448
MEST            (cg09872616) 0.688 0.117 0.386
MEST            (cg15164103) 0.210 0.148 0.235 0.111
MEST            (cg13917504) 0.586
MEST            (cg18183281) 0.171
MLH1            (cg10990993) 0.400 0.140 0.148 0.141 0.115
MLH1            (cg24607398) 0.100 0.164 0.158 0.179
MLH1            (cg03956628) 0.214 0.144 0.104
MLH1            (cg18320188)
MLH1            (cg02279071)
MLH1            (cg00893636)
MLH1            (cg13846866)
ARHGDIB    (cg10925082) 0.379 0.406 0.137 0.561
FLNA            (cg03672021) 0.122 0.153 0.203
COL1A1       (cg01234133) 0.675 0.133
COL1A1       (cg01593886) 0.147
FLNC            (cg02661879)
FLNC            (cg25664034) 0.150
NTS               (cg08888956) 0.361
PSMB9         (cg03465320) 0.161
    MDK             (cg00078194)
MDK             (cg18925548) 0.129
GLUL            (cg01419479)
GLUL            (cg17892328)
HSPA1A      (cg18424091)
NEFL             (cg13266631)
Values show |Δβ|≥0.1 between matched resistant and sensitive pairs of in vivo-derived cell lines, independently sorted SPs 
versus NSPs of IGROV1 cells and tumours at relapse versus matched primary tumours at presentation (7 pairs). Empty 
boxes indicate values of 0<|Δβ| <0.1. All CpG sites being differentially methylated between A2780 sensitive and resistant 
cell lines are depicted. 
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Figure 3.  
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Figure 4.  
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